Paul Emery presenting phase 2 data Peresolimab in RA. Novel mechanism aiming to restore immune homeostasis. Exciting for rheumatic disease beyond RA. @RheumNow #ACR22 #LateBreaking https://t.co/oOjvo5YmDB

Tam et al . Increased CV risk in early RA abrogated with treat to target approach. @RheumNow #ACR22 Abstr#1649 https://t.co/i2iHyPoKf0 https://t.co/u0R00oolyP

Reproductive concerns of adolescent patients with rheumatic disease Abstract #129 #ACR22 @RheumNow 🤰Worried about effects of dx and meds on fertility and pregnancy 💊Concerns about which birth control to use 🩸Effects of dx. on menstruation

Kimbrough et al. Comorbidities assoc serious infection in RA. Many! 26/55 comorbidities assoc serious infection. Number of comorbidities also assoc HR 1.16 (1.13-1.19) @RheumNow #ACR22 Abstr#1950 https://t.co/gnIlaJ037B https://t.co/6SR2Ej584w

RA asso w/ higher risk of lung cancer aHR 1.53, also in non-smokers aHR 1.66 🚬 Now this risk increases even more in pts w/ RA-ILD 🫁 aHR 3.06 No adjustment on occupation or non tobacco inhaled toxic exposure https://t.co/41ibPD6S3b Abs#1647 #ACR22 @RheumNow https://t.co/LNw792MYV0

Does Evusheld shield people living with rheumatic diseases? #ACR22 https://t.co/IutdoFxJUx https://t.co/FuKZEtpImm

#L02 #acr22 @rheumnow Bimekizumab ph3 in PsA: meaningful clinical improvement, improved mTSS, no new safety signals. Wk 52 ACR50: 53.0% PBO/BKZ, 54.5% BKZ, 50.0% ADA; MDA 53.7% PBO/BKZ, 55.0% BKZ, 52.9% ADA . mTSS change from baseline ≤0.5): 87.3% PBO/BKZ, 89.3% BKZ, 94.1% ADA https://t.co/NYRrPUBjt1

Yazici et al. IA Lorecivivint in Knee OA. 56 week DB-RCT of single injection at time 0. Didn't work. Not for primary endpoint (Pain NRS) or any PRO. @RheumNow #ACR22 Abstr#1639 https://t.co/66KyJW1zVz